CompanyDrug

Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera

CompanyDrug

Sanofi’s Tzield Wins FDA Priority Review for Pediatric T1D Expansion

CompanyDrug

Novo Nordisk, Lilly Cut China Prices for Wegovy, Mounjaro by Up to 80%

CompanyDeals

Lilly Nears $1 Billion Deal for Ventyx’s IBD Pipeline

Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal
CompanyDeals

Nimbus Therapeutics Partners with Eli Lilly on $1.3 Billion Obesity Drug Deal

Yifan Pharmaceutical's F-652 Wins NMPA IND for GVHD Therapy
CompanyDrug

Yifan Pharmaceutical’s F-652 Wins NMPA IND for GVHD Therapy

NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs
Policy / Regulatory

NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs

Mabwell's SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson's Trials
CompanyDeals

Mabwell’s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson’s Trials

Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases
CompanyDeals

Earendil Labs Partners with Sanofi on $2.56 Billion Bispecific Antibody Deal for Autoimmune Diseases

Ark Biopharma's Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years
CompanyDrug

Ark Biopharma’s Azstarys Approved in China for ADHD, First New Methylphenidate in 20 Years

Hengrui's HRS9531 and AR‑PROTAC Win NMPA IND Approval for Clinical Trials
CompanyDrug

Hengrui’s HRS9531 and AR‑PROTAC Win NMPA IND Approval for Clinical Trials

Genhouse Bio's MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals
CompanyDrug

Genhouse Bio’s MAT2A Inhibitor GH31 Wins NMPA and FDA Clinical Trial Approvals